Inventor · disambiguated record
Bernd Buchmann
Also filed as: BUCHMANN BERND · BUCHMANN BERND DR
39 granted patents·38 pending applications·261 citations·filing 1990–2021
97Inventor score
Top patents by PatentIndex Score
77 records- 0194US6225347B19-halogen-(Z)-prostaglandin derivatives, process for their production and their use as pharmaceutical agentsSCHERING AG·Filed 1994·Granted May 1, 2001·57 cites·20 claims
- 0287US6610736B116-Halogen-epothilone derivatives, method for producing them and their pharmaceutical useSCHERING AG·Filed 2000·Granted Aug 26, 2003·24 cites·56 claims
- 0384US7129270B2Nonsteroidal antiinflammatory agentsSCHERING AG·Filed 2005·Granted Oct 31, 2006·8 cites·34 claims
- 0483US5559134ALeukotriene-B4 antagonists, process for their production and their use as pharmaceutical agentsSCHERING AG·Filed 1993·Granted Sep 24, 1996·24 cites·11 claims
- 0581US7125893B16-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparationsSCHERING AG·Filed 2000·Granted Oct 24, 2006·11 cites·24 claims
- 0677US5880126A9H-Pyridu ((3,4-b) indole derivativesSCHERING AG·Filed 1996·Granted Mar 9, 1999·24 cites·4 claims
- 0776US7449459B2Inhibitors of soluble adenylate cyclaseBAYER SCHERING PHARMA AG·Filed 2007·Granted Nov 11, 2008·4 cites·22 claims
- 0876US6930102B216-halogen-epothilone derivatives, process for their production, and their pharmaceutical useSCHERING AG·Filed 2003·Granted Aug 16, 2005·7 cites·53 claims
- 0975US5414016ANew leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agentsSCHERING AG·Filed 1994·Granted May 9, 1995·15 cites·8 claims
- 1074US6777409B2Nonsteroidal antiinflammatory agentsSCHERING AG PATENTS·Filed 2001·Granted Aug 17, 2004·12 cites·48 claims
- 1172US7001916B1Epothilon derivatives, method for the production and the use thereof as pharmaceuticalsSCHERING AG·Filed 2000·Granted Feb 21, 2006·5 cites·20 claims
- 1272US5756818A9-chloro-prostaglandin derivativesSCHERING AG·Filed 1994·Granted May 26, 1998·24 cites·12 claims
- 1368US11427578B1Substituted pyrrolopyridine-derivativesBayer Pharma AG·Filed 2018·Granted Aug 30, 2022·1 cites·18 claims
- 1467US7166592B2Nonsteroidal antiinflammatory agentsSCHERING AG·Filed 2004·Granted Jan 23, 2007·3 cites·32 claims
- 1566US9655887B2Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraceptionBayer Pharma AG·Filed 2014·Granted May 23, 2017·1 cites·19 claims
- 1665US7645891B26-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparationsBAYER SCHERING PHARMA AG·Filed 2004·Granted Jan 12, 2010·1 cites·5 claims
- 1763US7935827B2Optically active, heteroaromatic β-hydroxy esters and processes for their preparation from β-keto esters and processes for the preparation of these β-keto estersBAYER SCHERING PHARMA AG·Filed 2008·Granted May 3, 2011·0 cites·9 claims
- 1862US5891910A9-halogen-(Z) prostaglandin derivatives, process for their production and their use as pharmaceutical agentsSCHERING AG·Filed 1995·Granted Apr 6, 1999·8 cites·18 claims
- 1962US2009018342A1New epothiolone derivatives, process for their production, and their pharmaceutical useKLAR ULRICH·Filed 2008·Application pending·0 cites
- 2057US7700621B26-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparationsBAYER SCHERING PHARMA AG·Filed 2005·Granted Apr 20, 2010·0 cites·28 claims
- 2155US7626035B2Optically active, heteroaromatic β-hydroxy esters and processes for their preparation from β-keto esters and processes for the preparation of these β-keto estersBAYER SCHERING PHARMA AG·Filed 2005·Granted Dec 1, 2009·0 cites·20 claims
- 2254US2023192700A1Pyrazolopyrazines acting on cancers via inhibition of cdk12BAYER AG·Filed 2021·Application pending·0 cites
- 2353US2005187270A116-Halogen-epothilone derivatives, method for producing them and their pharmaceutical useFiled 2005·Application pending·0 cites
- 2452US5440044ALeukotriene-B4 derivatives, process for their production and their use as pharmaceutical agentsSCHERING AG·Filed 1993·Granted Aug 8, 1995·3 cites·2 claims
- 2551US2010168179A16-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparationsKLAR ULRICH·Filed 2010·Application pending·0 cites
- 2651US2004058975A1Method for fertility controlSCHERING AG·Filed 2003·Application pending·0 cites
- 2750US2006040990A1Epothilone derivatives, process for their production, and their pharmaceutical useKLAR ULRICH·Filed 2005·Application pending·0 cites
- 2849US9394309B2Substituted phenylimidazopyrazoles and their useBAYER IP GMBH·Filed 2013·Granted Jul 19, 2016·0 cites·11 claims
- 2948US2023113037A1[1,2,4]triazolo[1,5-c]quinazolin-5-aminesBAYER AG·Filed 2020·Application pending·0 cites
- 3047US8841311B2Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicamentsBUCHMANN BERND·Filed 2009·Granted Sep 23, 2014·0 cites·7 claims
- 3147US5624943APyridine compounds which are useful as leukotriene-B4 -antagonistsSCHERING AG·Filed 1993·Granted Apr 29, 1997·3 cites·20 claims
- 3247US2015005288A1Substituted phenylimidazopyrazoles and use thereofBAYER IP GMBH·Filed 2013·Application pending·0 cites
- 3347US2007142675A1Method for producing c1-c15 fragments of epothilones and the derivatives thereofKLAR ULRICH·Filed 2004·Application pending·0 cites
- 3447US2010029599A1Indolylamides as modulators of the EP2 receptorBAYER SCHERING PHARMA AG·Filed 2009·Application pending·0 cites
- 3546US2010029598A1Extended Benzamide Derivatives as Modulators of the EP2 ReceptorBAYER SCHERING PHARMA AG·Filed 2009·Application pending·0 cites
- 3646US2006229305A1Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agentsBERGER MARKUS·Filed 2006·Application pending·0 cites
- 3745US7417066B2Inhibitors of soluble adenylate cyclaseSCHERING AG·Filed 2006·Granted Aug 26, 2008·0 cites·15 claims
- 3845US7407975B2Epothilone derivatives, method for producing same and their pharmaceutical useBAYER SCHERING PHARMA AG·Filed 1998·Granted Aug 5, 2008·2 cites·1 claims
- 3944US2008125435A11-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptorBRAUER NICO·Filed 2007·Application pending·0 cites
- 4044US2017037028A1Glucose transport inhibitorsBayer Pharma AG·Filed 2014·Application pending·0 cites
- 4144US2008004268A1Inhibitors of soluble adenylate cyclaseNGUYEN DUY·Filed 2007·Application pending·0 cites
- 4243US2004019088A1Use of Epothilones in the treatment of brain diseases associated with proliferative processesSCHERING AG·Filed 2003·Application pending·0 cites
- 4343US2009042913A1Indolylalkylthienopyrimidylamines as modulators of the EP2 receptorBRAEUER NICO·Filed 2008·Application pending·0 cites
- 4443US2006074084A1Inhibitors of soluble adenylate cyclaseNGUYEN DUY·Filed 2005·Application pending·0 cites
- 4543US2009042878A1Thienopyrimidylamines as modulators of the ep2 receptorBRAEUER NICO·Filed 2008·Application pending·0 cites
- 4643US2006079503A1Thiazolidinones and the use therof as polo-like kinase inhibitorsSCHERING AG·Filed 2003·Application pending·0 cites
- 4742US2016009725A1Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseasesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 4842US2009023738A1Diaminopyrimidines as modulators of the ep2 receptorBRAEUER NICO·Filed 2008·Application pending·0 cites
- 4942US2015376196A14-substituted pyrrolo- and pyrazolo-diazepinesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 5041US9062041B22H-indazoles as EP2 receptor antagonistsBAYER IP GMBH·Filed 2012·Granted Jun 23, 2015·0 cites·9 claims
Showing the top 50 of 77 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Bernd Buchmann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →